Skip to main content

Table 5 Univariate and multivariate analyses of progression-free survival according to clinical and treatment characteristics

From: Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study

Characteristics Patients, No. (%) mPFS (months) Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value
EGFR mutation subtype, No. (%)
Exon 19 deletion 68 (80.0) 16.0 0.31 (0.14–0.71)a 0.006 0.27 (0.12–0.58)a 0.001
Exon 21 L858R point mutation 11 (12.9) 8.7 0.34 (0.13–0.94)b 0.037 0.39 (0.15–1.03)b 0.058
 Rare and complex mutation 6 (7.1) 9.0     
Baseline symptomatic brain metastases, No. (%)
 No 60 (70.6) 14.3 0.67 (0.34–1.27)g 0.209 0.70 (0.37–1.32)g 0.267
 Yes 25 (29.4) 13.5     
ECOG performance status, No. (%)
 0–1 69 (81.2) 13.8 0.86 (0.39–1.90)g 0.703 0.86 (0.39–1.90)g 0.703
 2–4 16 (18.8) 15.9     
Abnormal organ function, No. (%)
 No 70 (82.4) 14.3 0.53 (0.25–1.09)g 0.086 0.50 (0.25–1.00)g 0.050
 Yes 15 (17.6) 8.8     
Afatinib dose adjustment, No. (%)
 Dose reduced 26 (30.6) 15.9 0.93 (0.44–1.99)c 0.854 0.72 (0.39–1.34)c 0.301
 Dose increased 10 (11.8) 13.5 2.35 (0.86–6.47)d 0.098 2.13 (0.93–4.88)d 0.075
 Starting dose maintained 49 (57.6) 13.4     
Optimal afatinib dose, No. (%)
 Less than 40 mg once daily 51 (60.0) 15.9 0.64 (0.32–1.28)e 0.209 0.47 (0.21–1.08)e 0.075
 50 mg once daily 4 (4.7) 13.5 0.97 (0.25–3.78)f 0.962 1.03 (0.27–4.01)f 0.962
 40 mg once daily 30 (35.3) 13.4     
  1. Abbreviations: PFS progression-free survival, mPFS median PFS, HR hazard ratio, 95% CI 95% confidence interval, EGFR epidermal growth factor receptor, ECOG Eastern Cooperative Oncology Group
  2. aexon 19 deletion versus exon 21 L858R point mutation; bexon 19 deletion versus rare and complex mutations
  3. cafatinib dose reduced versus starting dose maintained; dafatinib dose increased versus starting dose maintained
  4. eafatinib less than 40 mg once daily versus 40 mg once daily; fafatinib 50 mg once daily versus 40 mg once daily
  5. gthe second group was the reference category in logistic regression analysis